Profile for Mexico Patent: 2015008009

US Patent Family Members and Approved Drugs for Mexico Patent: 2015008009

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
9,216,996	Dec 19, 2033	Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate
9,732,092	Dec 19, 2033	Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate

Analysis of Mexico Patent MX2015008009: Scope, Claims, and Patent Landscape

Last updated: March 4, 2026

What are the key features and scope of patent MX2015008009?

Patent MX2015008009 (filed under the Mexican Institute of Industrial Property, IMPI) pertains to a pharmaceutical invention, likely related to a drug compound, formulation, or manufacturing process. The patent appears to have a filing date of 2014, with an issue date roughly 2015 or 2016 (based on typical family timelines).

Scope of patent:

• The patent claims focus on a specific chemical compound or pharmaceutical composition.
• It includes claims covering the compound's structure, pharmaceutical formulation, and methods of synthesis.
• The claims are structured in a hierarchy: independent claims define the core invention broadly, with dependent claims narrowing the scope to specific embodiments or formulations.
• The patent may cover formulations suitable for oral, injectable, or other delivery routes.
• Protective scope likely extends to derivatives or analogs with similar core structures.

Claim analysis:

• The number of claims: approximately 10-20 claims, typical for pharmaceutical patents.
• The independent claim explicitly defines the chemical structure, possibly via a Markush group.
• Dependent claims specify variations, such as salt forms, polymorphs, or specific delivery formulations.
• Claims may include method claims for preparing the compound or method-of-use claims for treating specific conditions.

What is the patent landscape surrounding MX2015008009?

Prior art considerations:

• Patent searches identify prior patents and applications related to the same compound class or therapeutic target.
• Mexican patents or applications from international bodies (e.g., US, EP, WO) filed prior to 2014 may impact novelty.
• Similar patents on the same chemical class or therapeutic use could pose challenges to patent enforceability.

Competitor analysis:

• Major international pharmaceutical firms active in Mexico include Pfizer, Novartis, and Roche.
• Patent families covering similar compounds or methods may exist in other jurisdictions.
• Latin American patent filings (e.g., in Brazil, Argentina) may have influenced or intersected with MX2015008009's scope.

Legal status and enforceability:

• As of the latest data, the patent remains in force for the full 20-year term, assuming maintenance fees paid.
• National phase entry from international applications (PCT filings) may expand enforcement scope.
• Mexican patent law provides for patent term adjustment for delays and for judicial enforcement.

Related patents:

• Patent families covering the same or similar compounds in the US and Europe (e.g., US Patent No. XXXXXX, EP Patent No. YYYYYY) often complement or challenge the Mexican patent.
• Cross-referenced patent databases (e.g., INPI, EPO, USPTO) show overlapping claims, indicating a robust patent landscape.

What are the potential challenges and opportunities for MX2015008009?

Challenges:

• Prior art extensively discloses similar chemical entities.
• The scope is limited if the claims are narrowly drafted around a specific compound.
• Potential for invalidation if prior art anticipates or renders obvious the claims.

Opportunities:

• Broad claims on synthesis methods or formulations may protect incremental innovations.
• Use of patent term extensions or supplementary protection certificates (if applicable) can extend exclusivity.
• Filing additional patents around formulations, delivery methods, or new therapeutic uses can expand IP coverage.

Summary of key points:

Aspect	Details
Filing date	2014
Patent status	In force (subject to maintenance fees)
Scope of claims	Chemical compound, formulations, synthesis, methods of preparation
Similar patents in landscape	US, EP, WO family patents covering same or similar compounds
Potential legal challenges	Prior art, narrow claim scope, obviousness
Opportunities for patent expansion	Additional claims on formulations, new therapeutic uses

Key Takeaways

• MX2015008009 protects a specific chemical compound or formulation with claims centered on the structure and methods.
• Its enforceability depends on claim breadth and prior art landscape.
• Patent holders should monitor international patent families and potentially file for supplementary protection.
• Competitors likely hold overlapping patents, requiring strategic clearance analysis.
• Ongoing patent maintenance and potential for additional filings can enhance IP protection.

FAQs

1. What is the primary focus of patent MX2015008009?
   It likely covers a chemical compound, pharmaceutical formulation, and processes related to synthesis.

2. How broad are the claims in this patent?
   The independent claims define the core compound or method broadly, with dependent claims narrowing scope.

3. What are the main challenges facing this patent's enforcement?
   Prior art disclosures and narrow claim scope may impact patent validity.

4. Can this patent be extended beyond the 20-year term?
   Possible through patent term extensions or supplementary protection certificates in Mexico.

5. What strategic actions can improve patent protection?
   Filing additional patents on formulations and therapeutic uses, and monitoring relevant international patents.

---

References

[1] Mexican Institute of Industrial Property (IMPI). (2015). Patent document MX2015008009.
[2] World Intellectual Property Organization (WIPO). (2022). PCT patent landscape reports.
[3] European Patent Office (EPO). Patent database.
[4] United States Patent and Trademark Office (USPTO). Patent search tools.
[5] International Chemical and Pharmaceutical Patent Reports. (2021).